Stanford

Michelle Shen

- MD Student, expected graduation Spring 2029
- MSTP Student

Publications

PUBLICATIONS

- **Identification of a 5-gene signature panel for the prediction of prostate cancer progression.** *British journal of cancer*
  Shen, M., García-Marqués, F., Muruganantham, A., Liu, S., White, J. R., Bermudez, A., Rice, M. A., Thompson, K., Chen, C. L., Hung, C. N., Zhang, Z., Huang, T. H., Liss, et al
  2024
- **ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.** *British journal of cancer*
  Shen, M., Liu, S., Toland, A., Hsu, E. C., Hartono, A. B., Alabi, B. R., Aslan, M., Nguyen, H. M., Sessions, C. J., Nolley, R., Shi, C., Huang, J., Brooks, et al
  2023
- **UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.** *Cell reports. Medicine*
  Liu, S., Chai, T., Garcia-Marques, F., Yin, Q., Hsu, E. C., Shen, M., Shaw Toland, A. M., Bermudez, A., Hartono, A. B., Massey, C. F., Lee, C. S., Zheng, L., Baron, et al
  2024: 101381
- **High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker.** *Scientific reports*
  Liu, S., Hawley, S. J., Kunder, C. A., Hsu, E. C., Shen, M., Westphalen, L., Auman, H., Newcomb, L. F., Lin, D. W., Nelson, P. S., Feng, Z., Tretiakova, M. S., True, et al
  2024; 14 (1): 486
- **ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype** *BRITISH JOURNAL OF CANCER*
  Shen, M., Liu, S., Toland, A., Hsu, E., Hartono, A. B., Alabi, B. R., Aslan, M., Nguyen, H. M., Sessions, C. J., Nolley, R., Shi, C., Huang, J., Brooks, et al
  2023
- **Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer.** *Methods in molecular biology (Clifton, N.J.)*
  Liu, S., Hsu, E. C., Shen, M., Aslan, M., Stoyanova, T.
  2022; 2472: 221-233
- **SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.** *Cell reports. Medicine*
  Rice, M. A., Kumar, V., Tailor, D., Garcia-Marques, F. J., Hsu, E., Liu, S., Bermudez, A., Kanchustambham, V., Shankar, V., Inde, Z., Alabi, B. R., Muruganantham, A., Shen, et al
  2022; 3 (2): 100502
- **Mesenchymal stromal cells for the treatment of Alzheimer's disease: Strategies and limitations.** *Frontiers in molecular neuroscience*
  Regmi, S., Liu, D. D., Shen, M., Kevadiya, B. D., Ganguly, A., Primavera, R., Chetty, S., Yarani, R., Thakor, A. S.
  2022; 15: 1011225
- **A novel oncogene mediated metabolic gene signature predicts breast cancer outcome.**
  Aslan, M., Hsu, E., Marques, F., Bermudez, A., Shen, M., Rice, M. A., Liu, S., West, R., Pitteri, S. J., Gyorffy, B., Stoyanova, T.
  AMER ASSOC CANCER RESEARCH.2021
- **Trop2 regulates prostate cancer growth and metastasis through distinct molecular mechanisms.**
  Stoyanova, T., Hsu, E., Liu, S., Marques, F., Bermudez, A., Aslan, M., Shen, M., Pitteri, S., Brooks, J. D.
  AMER ASSOC CANCER RESEARCH.2021

- **The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.** *American journal of clinical and experimental urology*
  Shen, M., Liu, S., Stoyanova, T.
  2021; 9 (1): 73-87
- **The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target** *AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY*
  Shen, M., Liu, S., Stoyanova, T.
  2021; 9 (1): 73–87
- **Oncogene-mediated metabolic gene signature predicts breast cancer outcome.** *NPJ breast cancer*
  Aslan, M., Hsu, E. C., Garcia-Marques, F. J., Bermudez, A., Liu, S., Shen, M., West, M., Zhang, C. A., Rice, M. A., Brooks, J. D., West, R., Pitteri, S. J., Győrffy, et al
  2021; 7 (1): 141
- **MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer.** *Scientific reports*
  Hsu, E. C., Shen, M., Aslan, M., Liu, S., Kumar, M., Garcia-Marques, F., Nguyen, H. M., Nolley, R., Pitteri, S. J., Corey, E., Brooks, J. D., Stoyanova, T.
  2021; 11 (1): 13305
- **Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay.** *Scientific reports*
  Liu, S. n., Garcia-Marques, F. n., Zhang, C. A., Lee, J. J., Nolley, R. n., Shen, M. n., Hsu, E. C., Aslan, M. n., Koul, K. n., Pitteri, S. J., Brooks, J. D., Stoyanova, T. n.
  2021; 11 (1): 7612
- **Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.** *Proceedings of the National Academy of Sciences of the United States of America*
  Hsu, E. C., Rice, M. A., Bermudez, A. n., Marques, F. J., Aslan, M. n., Liu, S. n., Ghoochani, A. n., Zhang, C. A., Chen, Y. S., Zlitni, A. n., Kumar, S. n., Nolley, R. n., Habte, et al
  2020
- **Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.** *British journal of cancer*
  Liu, S. n., Shen, M. n., Hsu, E. C., Zhang, C. A., Garcia-Marques, F. n., Nolley, R. n., Koul, K. n., Rice, M. A., Aslan, M. n., Pitteri, S. J., Massie, C. n., George, A. n., Brooks, et al
  2020